Pharmafile Logo
Pharmafocus logo
Advanced Search

Pfizer surprises industry by ending development of projected blockbuster

November 1, 2016
Research and Development Pfizer, cholesterol, clinical trials

Pfizer announced the news that it would no longer be developing an experimental cholesterol lowering drug. The drug had been …

News
cuba_us_flags

FDA approves clinical trial of Cuban lung cancer vaccine

November 1, 2016
Manufacturing and Production, Sales and Marketing Cuba, US, Vaccine, cimavax, clinical trials

The thawing of relations between the US and Cuba has allowed a pioneering treatment for non-small cell lung cancer to …

News

EMA has validated Merck and Pfizer’s MAA for avelumab

November 1, 2016
Manufacturing and Production, Sales and Marketing EMA, Merck KGaA, Pfizer, avelumab

The European Medicines Agency has validated the Marketing Authorisation Application for avelumab for the proposed indication of metastatic Merkel cell …

News

Woodley Equipment Company Exhibiting at Partnerships in Clinical Trials Europe 2016

November 1, 2016
PCT, clinical trials

Woodley Equipment Company is exhibiting at Partnerships in Clinical Trials Europe

News
Press release

Promising new study for children’s brain cancer

November 1, 2016
Manufacturing and Production brain cancer, children, oncology

There has been positive news coming from researchers at the Huntsman Cancer Institute, at the University of Utah, reporting on …

News
valeant

Hard times continue for Valeant as ex-CEO investigated for fraud

November 1, 2016
Manufacturing and Production CEO, Valeant, Valeant Pharmaceuticals, accounting, fraud

Valeant Pharmaceuticals continues to have a tough time after Bloomsberg broke the story of how former CEO J. Michael Pearson …

News
novartis_outside_1

Novartis breast cancer drug secures FDA fast-track status

November 1, 2016
Manufacturing and Production, Sales and Marketing Novartis, Pfizer, ibrance, letrozole, riboclib

Novartis has announced that its product ribociclib (LEE011) has been granted fast-track review status as a first-line treatment of advanced …

News
marc_weeks_takeda

Takeda appoint Marc Weeks to Digital Lead role

October 31, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Takeda, digital

Takeda UK have appointed Marc Weeks to the newly created role of digital lead. The creation of the role comes as …

Appointment

Ashfield walks away with gold at EVCOM Clarion Awards

October 31, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ashfield

The awards ceremony, held at The Seven Dials Club, Covent Garden, London on Friday 7 October, drew leading event and …

News
Press release
15813-a-senior-woman-receiving-a-vaccination-shot-from-her-doctor-pv

Influenza vaccine market to grow to £4.3 billion by 2025

October 31, 2016
Sales and Marketing influenza

GlobalData has released new findings which indicate that the seasonal influenza vaccine market is set to be worth $4.3 billion …

News

FDA rejects Sarilumab due to production facility issues

October 31, 2016
Manufacturing and Production, Sales and Marketing FDA, Regeneron, Sanofi, sarilumab

The US Food and Drugs administration has decided to reject the application for Sarilumab, Regeneron and Sanofi’s rheumatoid arthritis treatment, …

News
teva_copy

Teva sets out to delay generic competitor to Copaxone

October 31, 2016
Sales and Marketing Copaxone, Teva, Teva Pharmaceutical, generics

Teva Pharmacetuical, the Israel-based pharmaceutical company, submitted a document to the FDA on 30 October; the document outlines the differences …

News
astellas_tokyo_copy

Astellas snatches up oncology firm Ganymed for $1.4 billion

October 31, 2016
Research and Development, Sales and Marketing Astellas, Ganymed, IMAB362

Japanese pharma firm Astellas is set to bolster its oncology business with the acquisition of Ganymed Pharmaceuticals in a deal …

News
astrazeneca_logo_building

AstraZeneca’s head and neck cancer treatment clinical trials put on hold

October 31, 2016
Sales and Marketing AstraZeneca, clinical hold, clinical trials, immunotherapy, phase III

AstraZeneca, the Cambridge-based British company, had recruitment for its final stage Phase III trials placed on partial hold. The drug …

News
cynthia_chiaramitara

Novartis elects new MD for UK plant

October 28, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, appointment

Novartis has named Cynthia Chiaramitara as managing director of its plant in Grimsby, UK. She will take on the role …

Appointment
allergan

Allergan in $200 million purchase of biopharmaceutical

October 28, 2016
Medical Communications Allergan, Motus Therapeutics, Rythm Holding, Teva

Allergan will acquire Motus Therapeautics, a biopharmaceutical company that specialises in developing treatments for gastroparesis. It is another acquisition that …

News
4420456374_64a3d7e6aa

Top ten stories in the pharmaceutical industry this week

October 28, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing top ten

Halloween is creeping up, and its business as usual for the pharma industry; the week has been full of shockers, …

News
humacao_exterior

BMS unveils reorganisation plans & boosted profits

October 28, 2016
Business Services, Medical Communications Bristol-Myers Squibb, Yervoy, opdivo

BMS has announced its intention to restructure its operations alongside $3 billion share buyback and quarterly results which exceeded expectations.The …

News
3020361085_f37fb25e92_z

Male birth control injection has high efficacy but side-effects halt trials

October 28, 2016
Medical Communications WHO, birth control, male contraceptive, pregnancies

The study, funded by the World Health Organization, found a jab was close to 96% effective in tests to ascertain …

News
jj_sign_on_wall

J&J pays $70m over cancer allegations

October 28, 2016
Medical Communications JJohnson & Johnson, ovarian cancer

Johnson & Johnson has been forced to pay out $70 million after it was alleged that years of using the …

News
The Gateway to Local Adoption Series

Latest content

Sandoz launches allergy relief nasal spray in Germany and Switzerland

April 9, 2026

Japan approve Daiichi Sankyo’s Enhertu as a second-line treatment for gastric cancer

April 9, 2026

Trelleborg to take part in Medtec Japan 2026

April 8, 2026

Kainova Therapeutics expands phase I/II trial of antibody drug

April 7, 2026

Eisai starts enrolment for phase 2 narcolepsy study evaluating E2086

April 7, 2026